{
    "clinical_study": {
        "@rank": "114257", 
        "arm_group": [
            {
                "arm_group_label": "C - V - C+V", 
                "arm_group_type": "Experimental", 
                "description": "C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time"
            }, 
            {
                "arm_group_label": "V - C - C+V", 
                "arm_group_type": "Experimental", 
                "description": "C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time"
            }, 
            {
                "arm_group_label": "V - C+V - C", 
                "arm_group_type": "Experimental", 
                "description": "C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time"
            }, 
            {
                "arm_group_label": "C+V - V - C", 
                "arm_group_type": "Experimental", 
                "description": "C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time"
            }, 
            {
                "arm_group_label": "C+V - C - V", 
                "arm_group_type": "Experimental", 
                "description": "C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time"
            }, 
            {
                "arm_group_label": "C - C+V - V", 
                "arm_group_type": "Experimental", 
                "description": "C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators investigate the potential pharmacokinetic drug-drug interaction between\n      Cilnidipine 10 mg and Valsartan 160 mg in healthy male volunteers who receive Cilnidipine 10\n      mg alone, Valsartan 160 mg , and both together in a 3 period repeatedly."
        }, 
        "brief_title": "A Drug Interaction Study of Cilnidipine and Valsartan", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "To evaluate the safety, drug-tolerance, pharmacokinetics of Cilnidipine 10 mg  or Valsartan\n      160 mg monotherapy or Cilnidipine 10 mg and Valsartan 160 mg combination in healthy male\n      subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male volunteers, age 20 to 40 years\n\n          2. The result of Body Mass Index(BMI) is not less than 18.5 kg/m2 , no more than 25\n             kg/m2 and body weight are least 55 kg\n\n          3. Subjects who have no congenital or chronic disease and no abnormal symptom or opinion\n\n          4. Acceptable serum test, hematologic test, blood chemistry examination, urin test and\n             ECG, physical examination during screening\n\n          5. Subjects who have ability to comprehend the objectives, contents of study and\n             property of study drug before participating in trial and have willingness to sign of\n             informed consent in writing\n\n        Exclusion Criteria:\n\n          1. A subject with clinical evidence or history of hepatic (including carrier of\n             hepatitis virus), renal, respiratory, endocrine, neurologic, immunologic,\n             hematologic, oncologic, psychiatric, or cardiovascular disease\n\n          2. A subject with a history of gastrointestinal disease or surgery (except simple\n             appendectomy or repair of hernia), which can influence the absorption of the study\n             drug\n\n          3. A subject with history of  drug allergies (aspirin, antibiotics, including study drug\n             etc.), or history of clinically significant allergies\n\n          4. Systolic blood pressure <100mmHg or Diastolic blood pressure < 60 mmHg, systolic\n             blood pressure \u2265 150 mmHg or diastolic blood pressure \u2265 100mmHg(Sitting blood\n             pressure) during the screening procedure.\n\n          5. Presence or history of drug abuse or positive result in urine drug screening test\n\n          6. Use any prescriptive medication, Korean traditional medication not considered\n             acceptable by the clinical investigator during the last 14 days period before first\n             dosing, or use any OTC medication not considered acceptable by the clinical\n             investigator during the last 7 days period before first dosing (if used medication is\n             considered acceptable by investigator, patients can be included)\n\n          7. Participation in clinical trials of any drug within 60 days prior to the\n             participation of the study\n\n          8. Blood donation during 2 months or apheresis during 1 month before the study\n\n          9. Use of alcohol over 21 units/weeks\n\n         10. Smoker who smoke more than 20 cigarettes per day\n\n         11. A subject who takes grapefruit, grapefruit juice, or grapefruit-containing products\n             within 3 days prior to the participation of the study\n\n         12. A subject who takes St John's wort or some food including the  ingredient within 14\n             days prior to the participation of the study\n\n         13. Judged to be inappropriate for the study by the investigator after reviewing clinical\n             laboratory results or other reasons."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01838967", 
            "org_study_id": "ID_IDCV_1301"
        }, 
        "intervention": [
            {
                "arm_group_label": "C - V - C+V", 
                "description": "Drug will be administered to according to C - V - C+V sequence for 3 period.", 
                "intervention_name": "C - V - C+V", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "C - C+V - V", 
                "description": "Drug will be administered to according to C - C+V - V sequence for 3 period.", 
                "intervention_name": "C - C+V - V", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "V - C - C+V", 
                "description": "Drug will be administered to according to V - C - C+V sequence for 3 period.", 
                "intervention_name": "V - C - C+V", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "V - C+V - C", 
                "description": "Drug will be administered to according to V - C+V - C sequence for 3 period.", 
                "intervention_name": "V - C+V - C", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "C+V - V - C", 
                "description": "Drug will be administered to according to C+V - C - V sequence for 3 period.", 
                "intervention_name": "C+V - C - V", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "C+V - C - V", 
                "description": "Drug will be administered to according to C+V - V - C sequence for 3 period.", 
                "intervention_name": "C+V - V - C", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cilnidipine", 
                "Valsartan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cilnidipin and valsartn", 
            "pharmacokinetic drug drug interaction", 
            "oral administration", 
            "healthy male subjects"
        ], 
        "lastchanged_date": "October 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Jongno-gu", 
                    "country": "Korea, Republic of", 
                    "state": "Seoul", 
                    "zip": "110-744"
                }, 
                "name": "Seoul National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Randomized, Open-label, Single Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Cilnidipine 10 mg and Valsartan 160 mg After Oral Administration in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Kyoung Sang You, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Cmax of Cilnidipine 10 mg", 
                "safety_issue": "No", 
                "time_frame": "1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose"
            }, 
            {
                "measure": "Cmax of Valsartan 160 mg", 
                "safety_issue": "No", 
                "time_frame": "1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose"
            }, 
            {
                "measure": "AUClast of Cilnidipine 10 mg", 
                "safety_issue": "No", 
                "time_frame": "1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose"
            }, 
            {
                "measure": "AUClast of Valsartan 160 mg", 
                "safety_issue": "No", 
                "time_frame": "1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01838967"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tmax of Cilnidipine 10 mg", 
                "safety_issue": "No", 
                "time_frame": "1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose"
            }, 
            {
                "measure": "Tmax of Valsartan 160 mg", 
                "safety_issue": "No", 
                "time_frame": "1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose"
            }, 
            {
                "measure": "AUCinf of Cilnidipine 10 mg", 
                "safety_issue": "No", 
                "time_frame": "1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose"
            }, 
            {
                "measure": "CL/F of Cilnidipine 10 mg", 
                "safety_issue": "No", 
                "time_frame": "1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose"
            }, 
            {
                "measure": "AUCinf of Valsartan 160 mg", 
                "safety_issue": "No", 
                "time_frame": "1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose"
            }, 
            {
                "measure": "CL/F of Valsartan 160 mg", 
                "safety_issue": "No", 
                "time_frame": "1d(8d, 15d) pre-dose, 0.5, 1, 2, 2.5, 3, 4, 5, 6, 8, 12, 24h post-dose"
            }
        ], 
        "source": "IlDong Pharmaceutical Co Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "IlDong Pharmaceutical Co Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}